Veloxis Admits to Kickbacks, and to Pay Criminal Fines and Civil PenaltiesBOSTON, Aug. 15, 2026 /PRNewswire/ -- In a major healthcare fraud enforcement action, Veloxis Pharmaceuticals will pay over million and accept a stringent deferred prosecution agreement after admitting…
Judit Sharon calls on hospitals to ensure urgent clinical communications reach the right clinician or role, command attention, provide visibility into receipt and ownership, and escalate when unanswered. Key TakeawaysMessage delivery does not prove clinical accountability. A delivered message…
SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the…
LAGUNA HILLS, Calif. and SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led…
MANASSAS, Va., Aug. 8, 2026 /PRNewswire/ -- PureHealth Research is spotlighting the growing consumer interest in peptide nutrition and the role thoughtful nutritional choices play in maintaining healthy joints, skin and hair. Many of today's peptide supplements feature Morikol® Marine…
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias.RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND…
LUBBOCK, Texas, Aug. 6, 2026 /PRNewswire/ -- The Dr. Thanapoom Boonipat Grant for the Arts announces the opening of applications for its 2027 scholarship program, providing undergraduate students with an opportunity to showcase their original creative work through…
The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovis bio), Masitinib (AB Science), Remternetug (Eli Lilly), AUVELITY (AXS-05) (Axsome Therapeutics),…
Dual designations support development of a potential first disease-modifying therapy for an ultra-rare neurometabolic disorderBOSTON, Aug. 5, 2026 /PRNewswire/ -- Galibra Neuroscience announced a significant regulatory milestone with the receipt of both Orphan Drug Designation (ODD) and Rare…
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate…